Sorcha Curry1, Neva Patel1,2, Daniel Fakhry-Darian1, Sairah Khan2, Richard J Perry3, Paresh A Malhotra3,4, Kuldip S Nijran1,2, Zarni Win2. 1. 1Radiological Sciences Unit, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK. 2. 2Department of Nuclear Medicine, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK. 3. 3Department of Neurology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK. 4. 4Division of Brain Sciences, Imperial College London, UK.
Abstract
OBJECTIVE: To compare commercially available image analysis tools Hermes BRASS and Siemens Syngo.VIA with clinical assessment in 18F-Florbetapir PET scans. METHODS: 225 scans were reported by clinicians and quantified using two software packages. Scans were classified into Type A (typical features) or non-Type A (atypical features) for both positive and negative scans. For BRASS, scans with z-score ≥ 2 in 2 ≥ region of interest were classed positive. For Syngo.VIA a positive scan was indicated when mean cortical standardized uptake value ratio (mcSUVR) ≥ 1.17. RESULTS: 81% scans were Type A, and 19% scans were non-Type A. The sensitivity of BRASS and Syngo.VIA for Type A scans was 98.8 and 96.3%, specificity was 73 and 92%, respectively. Sensitivity for non-Type A scans was 95.8 and 79.2%, specificity was 36.8 and 57.9%, respectively.A third threshold of identifiable levels of plaque (1.08 ≤ mcSUVR ≤ 1.17) was recommended for Syngo.VIA to increase detection of false negative scans.The false positive rate of BRASS significantly decreased when an alternative positive threshold value of mcSUVR ≥ 1.18.Introduction of alternative criteria did not improve prediction outcome for non-Type A scans. More complex solutions are recommended. CONCLUSION: Hermes criteria for a positive scan leads to a high sensitivity but a low specificity. Siemens Syngo.VIA criteria gives a high sensitivity and specificity and agrees better with the clinical report. Alternative thresholds and classifications may help to improve agreement with the clinical report. ADVANCES IN KNOWLEDGE: Software packages may assist with clinical reporting of more difficult to interpret cases that require a more experienced read.
OBJECTIVE: To compare commercially available image analysis tools Hermes BRASS and Siemens Syngo.VIA with clinical assessment in 18F-Florbetapir PET scans. METHODS: 225 scans were reported by clinicians and quantified using two software packages. Scans were classified into Type A (typical features) or non-Type A (atypical features) for both positive and negative scans. For BRASS, scans with z-score ≥ 2 in 2 ≥ region of interest were classed positive. For Syngo.VIA a positive scan was indicated when mean cortical standardized uptake value ratio (mcSUVR) ≥ 1.17. RESULTS: 81% scans were Type A, and 19% scans were non-Type A. The sensitivity of BRASS and Syngo.VIA for Type A scans was 98.8 and 96.3%, specificity was 73 and 92%, respectively. Sensitivity for non-Type A scans was 95.8 and 79.2%, specificity was 36.8 and 57.9%, respectively.A third threshold of identifiable levels of plaque (1.08 ≤ mcSUVR ≤ 1.17) was recommended for Syngo.VIA to increase detection of false negative scans.The false positive rate of BRASS significantly decreased when an alternative positive threshold value of mcSUVR ≥ 1.18.Introduction of alternative criteria did not improve prediction outcome for non-Type A scans. More complex solutions are recommended. CONCLUSION: Hermes criteria for a positive scan leads to a high sensitivity but a low specificity. Siemens Syngo.VIA criteria gives a high sensitivity and specificity and agrees better with the clinical report. Alternative thresholds and classifications may help to improve agreement with the clinical report. ADVANCES IN KNOWLEDGE: Software packages may assist with clinical reporting of more difficult to interpret cases that require a more experienced read.
Authors: Adam S Fleisher; Kewei Chen; Xiaofen Liu; Auttawut Roontiva; Pradeep Thiyyagura; Napatkamon Ayutyanont; Abhinay D Joshi; Christopher M Clark; Mark A Mintun; Michael J Pontecorvo; P Murali Doraiswamy; Keith A Johnson; Daniel M Skovronsky; Eric M Reiman Journal: Arch Neurol Date: 2011-07-11
Authors: Matthias Brendel; Marcus Högenauer; Andreas Delker; Julia Sauerbeck; Peter Bartenstein; John Seibyl; Axel Rominger Journal: Neuroimage Date: 2014-12-04 Impact factor: 6.556
Authors: Christopher James Carswell; Zarni Win; Kirsty Muckle; Angus Kennedy; Adam Waldman; Gemma Dawe; Tara D Barwick; Sameer Khan; Paresh A Malhotra; Richard J Perry Journal: J Neurol Neurosurg Psychiatry Date: 2017-10-10 Impact factor: 10.154
Authors: Yi Su; Gina M D'Angelo; Andrei G Vlassenko; Gongfu Zhou; Abraham Z Snyder; Daniel S Marcus; Tyler M Blazey; Jon J Christensen; Shivangi Vora; John C Morris; Mark A Mintun; Tammie L S Benzinger Journal: PLoS One Date: 2013-11-06 Impact factor: 3.240
Authors: Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-07 Impact factor: 10.057